RenaSci Poster Publications
2009
Pharmacology of AMR-MCH-14 an antagonist of melanini-concentrating hormone receptor -1 for the treatment of obesity. Abstract No. 244. Keystone Symposium, Obesity: Novel Aspects of the Regulation of Body Weight, Alberta, 2009.
The novel and selective 5-HT6 receptor antagonist MEM 68753 reduces food intake and body weight in rats maintained on a high fat diet. Abstract No. 242. Keystone Symposium, Obesity: Novel Aspects of the Regulation of Body Weight, Alberta, 2009.
2008
Demonstration of the relationship between the in vivo dopamine efflux, behaviour and drug pharmacokinetics. Poster at College on the Problems of Drug Dependence Meeting, Washington, 2008.
Comparison of the effects of morphine and nicotine on noradrenergic function in the rat frontal cortex. Society for Research on Nicotine and Tobacco Rome. 2008
SLV-313: A dual acting D2 receptor antagonist/5-HT1A agonist Improves Glutamatergic-Induced Memory Impairment and Demonstrates anxiolytic- and antidepressant-like effects in rodents. Poster 155.16/CC4. Society for Neurosciences Meeting, Washington, 2008. Available online at www.sfn.org.
SLV-313: In vivo occupancy of D2 and 5-HT1A receptors by this dual acting D2 receptor antagonist/
5-HT1A agonist antipsychotic candidate. Poster 155.17/CC5. Society for Neurosciences Meeting, Washington, 2008. Available online at www.sfn.org.
Prevention of antipsychotic-induced weight-gain by the 5-HT6 agonist, E-6837. Poster 584.12/RR85. Society for Neurosciences Meeting, Washington, 2008. Available online at www.sfn.org.
Pharmacology of AMR-MCH-1, a MCH1 receptor antagonist for the treatment of obesity. Society for Neurosciences Meeting, Washington, 2008. Available online at www.sfn.org.
Effect of rimonabant on body weight, glucose tolerance, body composition and lipolysisin fa/faZucker rats: A comparison with pair-fed controls. Society for Neurosciences Meeting, Washington, 2008. Available online at www.sfn.org.
Development and validation of a radioligand receptor binding assay for MCH1 receptors using
[3H]AMR-MCH-1 in vitro and ex vivo. Society for Neurosciences Meeting, Washington, 2008. Available online at www.sfn.org.
The effect of chronic administration of sibutramine on body composition in dietary-induced, obese female Wistar rats – An evaluation of the Foss FoodScan™ analyser. P062: British Pharmacological Society Winter meeting, Brighton, 2008.
Comparative pharmacology of AMR-MCH-1 and AMR-MCH-2, MCH1 receptor antagonists for the treatment of obesity. PO64. British Pharmacological Society Winter meeting, Brighton, 2008.
MEM 68626, a selective serotonin 5-HT6 receptor antagonist as a potential treatment for alzheimer’s disease, mild cognitive impairment and obesity. American College of Neuropsychopharmacology, 47th Annual meeting, Arizona, 2008.
2007
The SH rat model of ADHD has profoundly different catecholaminergic responses to amphetamine’s enantiomers compared with Sprague-Dawleys. Abstract 386.14 Society for Neurosciences Meeting, San Diego, 2007. Available online at www.sfn.org.
A comparison using in vivo microdialysis of the catecholamine profiles of dexamphetamine and methylphenidate in an animal model of ADHD. Abstract 386.7. Society for Neurosciences Meeting, San Diego, 2007. Available online at www.sfn.org.
Effect of chronic administration of topiramate and phentermine alone and in combination in an animal model of dietary induced obesity. Poster 629.15/YY18. Society for Neurosciences Meeting, San Diego, 2007. Available online at www.sfn.org.
Effects of chronic administration of the novel CB1 ligand, E-6776, in a rat model of dietary-induced obesity. Joint Focused Meeting/3rd European Workshop on Cannabinoid Research, British Pharmacological Society, University of Nottingham. 2007.
2006
PSN S1 & S2 are novel 5-HT1A agonists and norepinepherine inhibitors which show anti-feeding efficiacy and superior cardiovascular safety to sibutramine in rats. Abstract 62.3 Society for Neurosciences Meeting, Atlanta, 2006. Available online at www.sfn.org.
Selective Y2 versus selective Y4 and combined Y2-Y4 receptor agonists for treatment of obesity. Oral communication at Gut Hormones and Other Regulators of Appetite Satiety and Energy Expenditure, New Mexico, 2006.
Modulation of the glutamatergic response to d amphetamine in the rat cerebral cortex by glial glutamate transporters. British Association for Psychopharmacology Summer Meeting, Oxford, 2006.
PRX-07034, a potent and selective 5-HT6 receptor antagonist, reduces food intake and body weight in rats. Proceedings of the Serotonin Club Sixth IUPHAR Satellite Meeting on Serotonin, 2006; Hokkaido, Japan (pp. P2-P17).
PRX-07034, a potent and selective 5-HT6 receptor antagonist, for the treatment of obesity. NAASO: The North American Obesity Society Annual Scientific Meeting October 20 - 24, Boston, 2006.
Characterisation of the catecholaminergic profiles of methyphenidate and its enantiomers in an animal model of ADHD by in vivo microdialysis. Abstract 97.4/0047. Society for Neurosciences Meeting, Atlanta, 2006. Available online at www.sfn.org
Effects of chronic administration and withdrawal of the novel 5-HT6 ligand, E-6837, in a rat model of dietary-induced obesity. Poster 62.2/X3. Society for Neurosciences Meeting, Atlanta, 2006. Available online at www.sfn.org
PRX-07034, a potent and selective 5-HT6 receptor antagonist, reduces food intake and body weight in dietary-induced obese rats. Poster 62.10/X11. Society for Neurosciences Meeting, Atlanta, 2006. Available online at www.sfn.org.
PSN S1 & PSNS2 are novel 5-HT1A agonists and norepinephrine reuptake inhibitors that reduce food intake and body weight in animals models of obesity. Poster 62.3/X4. Neurosciences Meeting Atlanta, 2006. Available online at www.sfn.org.
Prevention of hypertension and tachycardia in rats treated with the antiobesity agent sibutramine by co-administration with the 5-HT1A agonist F-11440. Poster 62.5/X6. Society for Neurosciences Meeting, Atlanta, 2006. Available online at www.sfn.org.
2005
Ex vivo occupancy as a technique to assess drug actions at multiple targets. Poster 447.6. Society for Neurosciences Meeting, Washington, 2005.
Microstructural analysis of the effects of sibutramine, d-fenfluramine and phentermine on food intake in the rat. IBC's 3rd Annual Targeting Metabolic Syndrome conference, Cambridge, USA, 2005.
Validation of an in vitro model of status epilepticus. Poster 432.12. Society for Neurosciences Meeting, Washington, 2005.
Comparison of the effects of rimonabant and sibutramine in a rat model of dietary induced obesity. Poster 532.13. Society for Neurosciences Meeting, Washington, 2005.
Comparison of the effects of rimonabant and sibutramine in an animal model of dietary-induced obesity. IBC's 3rd Annual Targeting Metabolic Syndrome Conference, Cambridge, USA, 2005.
Comparison of the effects of sibutramine and orlistat on body weight, food and water intake and body composition in dietary induced obese rats. IBC's 3rd Annual Targeting Metabolic Syndrome Conference, Cambridge, USA, 2005
Effects of HT-2157, a Galanin-3 receptor antagonist, on extracellular levels of 5-HT in various brain regions of freely-moving rats. 2005a; Proceedings of the British Pharmacological Society at http://www.pa2online.org/abstracts/Vol3Issue4abst167P.pdf.
The HT-2157 induced increase in extracellular 5-HT levels in the frontal cortex of freely-moving rats is modulated by 5-HT1A receptors. 2005b; Proceedings of the British Pharmacological Society at http://www.pa2online.org/abstracts/Vol3Issue4abst165P.pdf
Use of the Culex Bambino to measure brain neurotransmitters, plasma corticosterone and drug levels with behaviour in the same freely moving rat. Poster 921.5. Society for Neurosciences Meeting, Washington, 2005.
Comparison of the effects of rimonabant, sibutramine and orlistat on acute food intake and in a model of dietary induced obesity in the mouse. Poster 532.12. Society for Neurosciences Meeting, Washington, 2005.
2004
Microstructural analysis of the effects of sibutramine, d-fenfluramine and phentermine on food intake in the rat. Abstract 76.19. Society for Neurosciences Meeting, San Diego, 2004.
The ketone, KTX 0101, protects hippocampal neurones in an in vitro model of status epilepticus. Abstract 1013.15. Poster 906.7, Society for Neurosciences Meeting, San Diego, 2004.
Comparison of the effects of sibutramine and orlistat on body weight, food and water intake and body composition in dietary-induced obese rats. Poster 76.19 Society for Neurosciences Meeting, San Diego, 2004.
The reversal of delay dependent deficits in the novel object recognition model by the 5-HT6 receptor antagonist, SB-399885. http://www.pa2online.org/abstracts, 2004, 076P.
Validation of an in vitro model of status epilepticus. http://www.pa2online.org/abstracts, 2004, 087P.
Attenuation of defensive burying by mice following MDMA, methamphetamine and methylphenidate. Proceedings of the British Association for Psychopharmacology Summer Meeting, Harrogate, 2004.
Neurochemical interactions of nicotine and bupropion in the rat striatum. Proceedings of the British Association for Psychopharmacology Summer Meeting, Harrogate, 2004.
2002
Mazindol directly increases adipocyte lipolysis. 62nd American Diabetes Association meeting, Diabetes Poster number 360-P. San Francisco, 2002.
In vivo, dual-probe, microdialysis study of the effects of local infusion of d amphetamine on noradrenaline efflux in rat hypothalamus and frontal cortex. Br. J. Pharmac., 135, 347P, 2002.
Inhibition of 5-hydroxytryptamine synthesis increases d-amphetamine evoked release of noradrenaline in the frontal cortex and the hypothalamus of freely moving rats: A dual-probe microdialysis study. Proceedings of the FENS 2002 Meeting, Paris, 2002.
Inhibition of 5-hydroxytryptamine synthesis increases d-amphetamine evoked efflux of noradrenaline: A dual-probe microdialysis study in the frontal cortex and hypothalamus of freely-moving rats. Proceedings of the British Association for Psychopharmacology Meeting, Harrogate, 2002.
2001
Anti-obesity effect of 3-guanidinopropionic acid, Annual Conference Diabetes UK, Glasgow. 2001.